Pramlintide: all 43 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 DiabetesRecruitingNCT06046417Phase 2/3
• Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1DCompletedNCT04074317Phase 2Results posted
• Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes MellitusCompletedNCT02500979Phase 1Results posted
• Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass SurgeryCompletedNCT01841359Phase 4Results posted
• Use of Exenatide and Pramlintide to Decrease Post-prandial HyperglycemiaCompletedNCT01269047Phase 4Results posted
• A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsTerminatedNCT01235741Phase 2Results posted
• Pramlintide in Adolescents With Type 1 DiabetesCompletedNCT00842075Not applicableResults posted
• Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinCompletedNCT00819234Phase 2Results posted
• Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaCompletedNCT00690235Phase 4Results posted
• Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsCompletedNCT00673387Phase 2Results posted
• A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesCompletedNCT00467649Phase 4Results posted
• Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes MellitusCompletedNCT00442767Phase 4Results posted
• A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsCompletedNCT00392925Phase 2Results posted
• Tailoring Obesity Treatment TrialWithdrawnNCT06619015Phase 2/3
• A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 DiabetesCompletedNCT05199714Not applicable
• Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot StudyWithdrawnNCT04252612Early Phase 1
• Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 DiabetesStatus unknownNCT04243629Not applicable
• Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseActive, not recruitingNCT03560960Early Phase 1
• Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DMCompletedNCT01708044Phase 1
• Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes MellitusWithdrawnNCT01165944Phase 1/2
• Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes MellitusStatus unknownNCT01137695Phase 3
• The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 DiabetesCompletedNCT00950677Phase 4
• Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DMWithdrawnNCT00732147Not applicable
• A Study of the Functional Magnetic Resonance Imaging Response to Leptin and PramlintideStatus unknownNCT00691158Not applicable
• Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 DiabetesWithdrawnNCT00505882Phase 4
• A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 DiabetesCompletedNCT00502138Phase 4
• Effect of Hyperglycemia on Gastric Emptying Interactions With PramlintideCompletedNCT00489645Not applicable
• The Effect of Pramlintide on Meal Time Insulin BolusCompletedNCT00460304Not applicable
• Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsCompletedNCT00444561Phase 2
• A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsCompletedNCT00402077Phase 2
• A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes MellitusCompletedNCT00313183Phase 2
• Continuous Subcutaneous Infusion of Pramlintide and InsulinCompletedNCT00291772Phase 4
• A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 DiabetesCompletedNCT00240253Phase 4
• The Effect of Prolonged Pramlintide Infusion in Pediatric DiabetesCompletedNCT00206297Phase 3
• The Role of Amylin and Glucagon in T1DMCompletedNCT00206258Phase 3
• A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsCompletedNCT00189514Phase 2
• A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsCompletedNCT00112021Phase 2
• Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusCompletedNCT00108004Phase 3
• Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes MellitusCompletedNCT00107107Phase 3
• Evaluation of an Orally Administered Medication When Taken in Conjunction With PramlintideCompletedNCT00044707Phase 2
• Evaluation of the Effect of Pramlintide on Satiety and Food IntakeCompletedNCT00042601Phase 2
• Evaluation of the Bioavailability of PramlintideCompletedNCT00042471Phase 2
• Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose ControlCompletedNCT00042458Phase 3

← Pramlintide overview